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Summary
Background Fluid resuscitation is the recommended management of shock, but increased mortality in febrile African 
children in the FEAST trial. We hypothesised that fluid bolus-induced deaths in FEAST would be associated with 
detectable changes in cardiovascular, neurological, or respiratory function, oxygen carrying capacity, and blood 
biochemistry.
Methods We developed composite scores for respiratory, cardiovascular, and neurological function using vital sign 
data from the FEAST trial, and used them to compare participants from FEAST with those from four other cohorts 
and to identify differences between the bolus (n=2097) and no bolus (n=1044) groups of FEAST. We calculated the 
odds of adverse outcome for each ten-unit increase in baseline score using logistic regression for each cohort. Within 
FEAST participants, we also compared haemoglobin and plasma biochemistry between bolus and non-bolus patients, 
assessed the effects of these factors along with the vital sign scores on the contribution of bolus to mortality using Cox 
proportional hazard models, and used Bayesian clustering to identify subgroups that differed in response to bolus. 
The FEAST trial is registered with ISRCTN, number ISRCTN69856593.
Findings Increasing respiratory (odds ratio 1·09, 95% CI 1·07–1·11), neurological (1·26, 1·21–1·31), and cardiovascular 
scores (1·09, 1·05–1·14) were associated with death in FEAST (all p<0·0001), and with adverse outcomes for specific 
scores in the four other cohorts. In FEAST, fluid bolus increased respiratory and neurological scores and decreased 
cardiovascular score at 1 h after commencement of the infusion. Fluid bolus recipients had mean 0·33 g/dL (95% CI 
0·20–0·46) reduction in haemoglobin concentration after 8 h (p<0·0001), and at 24 h had a decrease of 1·41 mEq/L 
(95% CI 0·76–2·06; p=0·0002) in mean base excess and increase of 1·65 mmol/L (0·47–2·8; p=0·0070) in mean 
chloride, and a decrease of 0·96 mmol/L (0·45 to 1·47; p=0·0003) in bicarbonate. There were similar effects of fluid 
bolus in three patient subgroups, identified on the basis of their baseline characteristics. Hyperchloraemic acidosis 
and respiratory and neurological dysfunction induced by saline or albumin bolus explained the excess mortality due 
to bolus in Cox survival models.
Interpretation In the resuscitation of febrile children, albumin and saline boluses can cause respiratory and 
neurological dysfunction, hyperchloraemic acidosis, and reduction in haemoglobin concentration. The findings 
support the notion that fluid resuscitation with unbuffered electrolyte solutions may cause harm and their use should 
be cautioned. The effects of lower volumes of buffered solutions should be evaluated further. 
Funding Medical Research Council, Department for International Development, National Institute for Health 
Research, Imperial College Biomedical Research Centre.
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Introduction
Both adult and paediatric resuscitation guidelines 
recommend boluses of intravenous fluid, most commonly 
crystalloid or colloid solutions, with 20–60 mL/kg body­
weight being recommended in the first hour of re­
suscitation.1,2 The practice of volume expansion by rapid 
bolus infusion was introduced not on the basis of 
evidence from randomised trials, but on current 
understanding of the physiology of shock. Patients with 
sepsis or other forms of shock, whether arising from 
external blood or fluid losses, internal fluid loss from 
capillary leakage, or pathological vasodilatation, are 
thought to be hypovolaemic and thus to have diminished 
venous return to the heart. Clinical experience has 
supported this physiological concept because bolus 
resuscitation is usually associated with improved pulse 
pressure, warming of the peripheries, and increased 
urine output. However, clinicians are also aware that 
some patients deteriorate, rather than improve, after 
volume resuscitation. Furthermore, patients receiving 
large volumes of fluid are known to develop generalised 
oedema,1,2 often accompanied by increased requirement 
for high ventilation pressures, unless fluid is removed by 
haemofiltration or diuresis. Despite these known adverse 
effects of fluid, bolus fluid resuscitation is so widely 
accepted in the practice of emergency medicine in 
resource­rich countries that neither clinicians nor 
research ethics committees are likely to agree to test the 
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practice in a randomised controlled trial with a no­fluid 
bolus control.
By contrast with practice in resource­rich countries, 
fluid bolus resuscitation is not routine in Africa 
and other resource­poor regions. There has been an 
equipoise in many African hospitals between clinicians 
who recommend fluid resuscitation and those who avoid 
rapid fluid bolus resuscitation for fear that it might result 
in pulmonary or cerebral oedema. It was this equipoise in 
the use of fluids for resuscitation that motivated the 
FEAST (Fluid Expansion As Supportive Treatment) trial.3 
In FEAST, 3141 febrile children with signs of under­
perfusion in Uganda, Kenya, and Tanzania were randomly 
allocated to receive 20–40 mL/kg of normal saline or 
albumin bolus or maintenance only fluids. There was 
surprise both among the investigators as well as the wider 
Research in context
Evidence before this study
Fluid resuscitation has been recommended initial treatment of 
sepsis and septic shock for more than 40 years. The practice of 
fluid resuscitation in sepsis has strong theoretical and 
physiological justification, because volume expansion is 
believed to correct the hypovolaemia occurring in sepsis due to 
capillary leak and pathological vasodilatation, and thus 
increases cardiac output by achieving a more favourable 
position on the Starling curve.
We searched PubMed from Sept 1, 1974, to July 31, 2018, 
using the search term “fluid resuscitation in sepsis” restricting 
the search to human studies, and English language.
We identified 1827 publications, including reviews, 
observational studies, and clinical trials. We found numerous 
observational studies and randomised trials comparing 
different types of fluid resuscitation, including colloids 
(albumin, gelatin, dextrans, and starch) and different 
crystalloids (normal saline, hypertonic saline, Ringer’s lactate, 
and other balanced salt solutions). We identified only one 
randomised controlled trial (the FEAST trial) in which volume 
resuscitation by itself was compared with maintenance fluids 
alone. In the FEAST trial, more than 3000 children with fever 
and clinical signs of impaired perfusion were randomly assigned 
to volume resuscitation with boluses of 5% albumin or normal 
saline, or maintenance fluids alone. The trial was stopped 
because of increased mortality in the bolus groups. Since FEAST 
is the only randomised controlled trial comparing bolus volume 
expansion with a no bolus control group, and showed harm 
from fluid expansion, it provides unique data through which to 
understand the physiological effects of fluid resuscitation.
Added value of this study
The findings of the FEAST trial—that volume expansion with 
20-40 mL/kg of normal saline or albumin increased mortality in 
critically ill children, compared with no bolus—has been 
intensively debated by the intensive care and resuscitation 
community, and has left practitioners uncertain as to what the 
best resuscitation practice should be. To date, there has been no 
clear explanation as to why volume resuscitation was harmful 
in FEAST. Because FEAST was done in resource-poor hospitals 
in Africa, where other aspects of intensive care were not 
available, including mechanical ventilation and inotropic drugs, 
it provides unique data about the physiological effects of bolus 
volume expansion without the interference of other intensive 
care methods.
We compared sequential haemodynamic and vital sign data, 
haemoglobin, and blood chemistry in the bolus and no bolus 
groups of FEAST. Using novel composite scores to compare 
changes in respiratory, cardiovascular, and neurological 
function between the bolus and no bolus groups, we found 
that volume expansion with either 5% albumin or normal 
saline caused worsening of respiratory function and increased 
signs of raised intracranial pressure, but improved 
cardiovascular function. Bolus recipients had lower 
haemoglobin concentrations at 8 h, lower bicarbonate, and 
increased base deficit and chloride at 24 h after the bolus 
infusion. Regression modelling using the physiological 
variables significantly altered by bolus suggest that the 
increased mortality in FEAST can be explained by 
bolus-induced worsening in respiratory and neurological 
function, haemodilution, and hyperchloraemic acidosis.
Implications of all the available evidence
Despite the universal belief that volume expansion with 
crystalloid or colloidal fluid is beneficial in sepsis, and the 
inclusion of bolus volume expansion in current treatment 
recommendations, the FEAST trial showed fluid bolus 
increased mortality. The results of our analysis of the vital 
signs, haematological data, and biochemical data from FEAST 
provide a biologically plausible explanation for the adverse 
outcomes associated with bolus fluids. A modest bolus 
(20-40 mL/kg) of normal saline or albumin resulted in 
prolonged hyperchloraemic acidosis, reduced haemoglobin 
concentration, and worse respiratory and neurological 
function in the early hours after infusion, despite transient 
improvement in cardiovascular function, and explained the 
increase mortality in bolus recipients. Of these effects, 
saline-induced hyperchloraemic acidosis was a major 
contributor to the adverse outcome in bolus recipients. 
Our data suggest that normal saline and other unbuffered 
crystalloid solutions should be avoided in resuscitating 
seriously ill patients. Because volume resuscitation is 
associated with deterioration of respiratory function and 
neurological function in some patients, caution in use of fluids 
might be needed in patients with respiratory or CNS 
compromise, and trials of lower volumes of buffered solutions 
are now needed to establish whether the beneficial effects of 
fluid on cardiovascular function can be achieved with less risk 
of respiratory and neurological compromise.
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scientific community when the trial was stopped by the 
study data and safety monitoring group after 3141 patients 
had been recruited, because of clear evidence of increased 
incidence of death in the recipients of bolus fluids.3
Since publication of the FEAST trial in 2011, there has 
been extensive debate about the generalisability of the 
findings and their implications for practice.4–14 The 
surprising finding, that a common medical intervention 
increased mortality in the only randomised controlled 
trial ever done to test fluid resuscitation against a no 
bolus control, has raised several important questions. 
What were the mechanisms by which fluid resuscitation 
increased mortality in FEAST? Were the findings specific 
to the population of patients in east Africa included in 
the study, or are they relevant to patients globally? Were 
there subgroups of patients included in the FEAST trial 
who were adversely affected by bolus, whereas others 
experienced benefit? Was the adverse effect due to the 
nature of the fluids used (normal saline and 5% albumin, 
both high chloride solutions) rather than the volume 
infused? Should international recommendations for 
fluid resuscitation be altered on the basis of this trial?
Research ethics committees in Africa and other 
resource­poor regions are unlikely to approve further 
trials of fluid resuscitation in light of the increased 
mortality shown in FEAST. Conversely, neither clinicians 
nor ethics committees in most resource­rich countries 
are likely to approve a trial in which fluid bolus is withheld 
from critically ill patients, because of the widely held 
belief in the benefits of fluid resuscitation. Many 
clinicians involved in emergency care in Europe and 
North America have chosen to disregard the results of the 
FEAST trial as being unique to the African context and 
argue that the findings are not relevant in well resourced 
settings, where the availability of ventilators and inotropes 
can ameliorate any negative effects of bolus fluids.9 The 
findings from FEAST have thus confused current clinical 
practice in resuscitation, raising the question of whether 
the current standard intervention to rapidly expand 
circulating volume is harmful and perhaps increases 
deaths and admissions to intensive care.
In light of the unresolved questions raised by FEAST, 
we believed that there was both a need and an obligation 
to fully use all the available data from the FEAST trial to 
understand why fluid bolus was associated with increased 
mortality. We postulated that the increased mortality in 
bolus recipients resulted from a measurable adverse 
effect of bolus fluids on cardiovascular function, 
respiratory function, raised intracranial pressure or 
neurological function, oxygen carrying capacity, or the 
biochemical and acid base status of bolus recipients. To 
test this hypothesis we developed composite scores to 
measure respiratory function, cardiovascular function, 
and identify raised intracranial pressure, using sequential 
vital sign data from FEAST, and compared the function 
of each system, as well as plasma biochemistry and acid­
base balance, in the bolus and no bolus groups of FEAST.
Methods
Study design
We hypothesised that fluid bolus­induced deaths in 
FEAST would be associated with detectable changes in 
cardiovascular, neurological, or respiratory function, 
oxygen carrying capacity, or blood biochemistry. Several 
scoring systems exist to predict severity and outcome in 
paediatric intensive care.15–18 However, these existing 
scores do not enable evaluation of changes in individual 
organ systems because they combine markers of 
dysfunction of multiple organ systems. Furthermore, 
these scores use blood or intensive care variables that are 
not routinely available in the low­resource settings where 
FEAST was done. There are no reliable and established 
methods to quantify the severity of cardiovascular 
dysfunction, respiratory dysfunction, or raised intracranial 
pressure, outside of an intensive care setting. To analyse 
the effects of fluid bolus on physiological status of each 
organ system, we developed composite scores to describe 
respiratory, cardiovascular, and neurological function. We 
assessed their validity by comparison and analysis of their 
relationships in all available data from FEAST and four 
other cohorts of ill children, and then used the composite 
scores to identify differences in respiratory, neurological, 
and cardiovascular function between the bolus and no 
bolus groups of FEAST. We also compared changes in 
acid­base balance and haemoglobin concentration in 
bolus and no bolus groups of FEAST. The overall structure 
of the study and the pre­planned and post­hoc analyses are 
shown in figure 1.
Participants
We analysed data from FEAST and two published 
paediatric studies of critically ill children (meningo coccal 
disease in the UK, and cerebral malaria in Malawi)3,19,20 
together with data from two unpublished cohorts (one 
from South Africa, the other from St Mary’s Hospital 
emergency department in London, UK).
In the FEAST study,3 between Jan 13, 2009, and 
Jan 13, 2011, 3170 patients with fever, respiratory distress, 
or prostration and impaired perfusion were enrolled. 
3141 were randomly assigned to either maintenance 
fluids only (4 mL/kg per h; n=1044), or to receive boluses 
of 20 mL/kg albumin (n=1050) or normal saline (n=1047) 
in the first hour, with a further 20 mL/kg if signs of 
impaired perfusion persisted.3 Clinical details of patients 
in FEAST have been described in detail.3,21,22 Vital signs 
were assessed in surviving children at 1 h, 4 h, 8 h, 24 h, 
and 48 h after commencing fluid bolus in the albumin 
and saline groups, or after randomisation in the control 
group (appendix p 21).
In the UK meningococcal disease study,19 148 fatal cases 
and 354 survivors with meningococcal sepsis in England 
and Wales were enrolled between Dec 1, 1997, and 
Feb 28, 1999. The cohort has been described previously.19
In the Malawian cerebral malaria cohort, between 
Jan 4, 2010, and June 5, 2011, 448 children with cerebral 
See Online for appendix
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malaria were admitted to Queen Elizabeth Central 
Hospital, Blantyre, Malawi, and reported in a study of 
raised intracranial pressure.20 Vital signs and clinical 
variables recorded on admission were related to outcome.
In the South African cohort, 61 children receiving fluid 
resuscitation for presumed sepsis and gastroenteritis at 
Red Cross Children’s Hospital, Cape Town, South Africa 
were recruited between Feb 1, 2013, and June 1, 2013. Vital 
signs and other clinical details were recorded on 
admission to hospital and related to outcome (admission 
to intensive care or death).
In the St Mary’s cohort, vital sign data and outcome 
(the need for hospital admission or intensive care 
admission) were collected for 18 863 children attending 
the emergency department at St Mary’s Hospital, 
London, UK, from June 10, 2014, to March 9, 2015.
All studies were approved by the institutional review 
board of the relevant centre. Details of the recruitment 
procedure, consent procedures, ethics, and institutional 
approvals for the FEAST, meningococcal, and Malawian 
cerebral malaria studies have been reported.3,19,20 Access to 
the FEAST trial data was provided after a formal request 
to the trial study group. Data collection for the  South 
African sepsis cohort and St Mary’s Hospital cohort were 
approved by the local research ethics committee of 
University of Cape Town (HREC REF 025/2013) and UK 
(14/LO/0266), respectively; in accordance with these 
approvals, written informed consent was obtained only 
for participants who had additional data or samples 
collected beyond those necessary for routine clinical care. 
The data from each study were made available with 
approval of the individual country investigators. The 
Figure 1: Study overview
We developed physiological scores to describe respiratory, neurological, and cardiovascular function, and compared them between FEAST and four additional cohorts 
of ill children. We assessed their relationships with clinical outcomes. We used the scores to describe sequential changes in each organ system in FEAST and to identify 
clusters of participants with differing physiological derangements within FEAST. We then assessed the effect of fluid bolus on subsequent physiological scores, 
haemoglobin, and acid-base biochemistry in FEAST participants using a linear model accounting for baseline values as the primary outcome measure. The proportion 
of individuals with larger, more clinically important changes in physiological scores and blood parameters were compared in a secondary analysis. The effect of bolus 
volume on physiological scores, haemoglobin, and biochemical parameters was assessed in pre-planned exploratory analyses. The combined contribution of the 
effects of bolus on time to death was assessed in a post-hoc analysis.
Develop physiological scores to 
describe respiratory, cardiovascular 
and neurological status based on 
available vital sign data in FEAST
Calculate physiological scores at 
sequential time points in FEAST to 
describe changes in physiology and 
their association with bolus
Evaluate association of physiological 
scores with outcomes in FEAST, 
other cohorts and clusters within 
FEAST
Compare baseline physiological 
scores in FEAST with other cohorts of 
subjects with different severity and 
causes of illness
Use physiological scores, 
haemoglobin and lactate 
measurements to identify clusters of 
subjects in FEAST with different 
baseline features
Linear model analyses of the effect of 
fluid bolus on physiological scores, 
biochemical parameters, 
and haemoglobin
Comparisons of the proportions of 
individuals with larger derangements 
in physiological scores, biochemical 
measurements, and haemoglobin, 
between bolus and no bolus groups
Sequential biochemical and 
haemoglobin measurements in 
FEAST
1. Development and validation 
of physiological scores
2. Pre-planned primary 
analysis
3. Pre-planned secondary 
analysis
4. Pre-planned exploratory 
analysis
5. Post-hoc analysis
Comparisons of the proportions of 
individuals with larger derangements 
in physiological scores, biochemical 
measurements, and haemoglobin, 
by volume of fluid received
Multivariate model to determine 
association between time to death 
and combination of bolus-induced 
changes in physiological scores, 
biochemical parameters, and, 
haemoglobin
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analysis of  factors affecting outcome in each study were 
covered by the ethics approval of each study. 
Outcomes 
We analysed the distribution of respiratory, cardiovascular, 
and neurological function scores among FEAST 
participants and within each of the four cohorts, and for 
FEAST compared scores between those who received 
bolus and those who did not. We used logistic regression 
to calculate the odds of adverse outcome (death in FEAST 
and the UK meningococcal disease cohort, neurological 
sequelae or death in the Malawian cohort, intensive care 
admission or death in the South African cohort, and 
admission to hospital or intensive care admission in the 
St Mary’s cohort) for each ten­unit increase in baseline 
score. Within FEAST participants, we examined the effect 
of bolus on the proportion of patients with extreme 
derangement of vital sign scores or physiological para­
meters, and assessed the effect of volume of fluid 
administered. Finally, we used Bayesian analysis to 
identify subgroups with differing physiological derange­
ment who might differ in response to fluids, and to 
explore how the multiple simultaneous physiological 
changes caused by fluid bolus were associated with excess 
deaths in bolus recipients.
Procedures
The physiological basis and development of composite 
scores for respiratory function, cardiovascular function, 
and detection of raised intracranial pressure and 
neurological function are described in detail in the web 
appendix (pp 3–6).
To assess respiratory compromise we used respiratory 
rate (which increases as respiratory function worsens) 
and oxygen saturation (which decreases as respiratory 
function worsens). Vital signs were normalised as 
described in the appendix, with published normal values. 
We converted age­adjusted degree of tachypnoea and 
pulse oximetry measurements to the same direction of 
effect and weighted the contribution of oxygen saturation:
Respiratory score=(respiratory rate – mean respiratory 
rate for age) + 5 × (100 – oxygen saturation)
Cardiovascular responses to developing shock maintain 
blood pressure with vasoconstriction and increasing heart 
rate. If these fail, blood pressure falls. We combined age­
adjusted degree of tachycardia, age­adjusted degree of 
hypotension, and weighted peripheral capillary refill time 
into a measure of cardiovascular compromise:
Cardiovascular score=(heart rate – mean heart rate for 
age) + (mean systolic blood pressure for age –systolic 
blood pressure) + 25 × (capillary refill time)
Raised intracranial pressure is associated with 
decreasing conscious level, bradycardia, and hypertension 
(the latter two are components of Cushing’s triad).23–25 We 
combined weighted level of consciousness measured on 
the AVPU scale (alert=0; responds to verbal stimulus=1; 
responds to painful stimulus=2; unresponsive=3),26 and 
age­adjusted degree of hypertension, and age­adjusted 
degree of bradycardia:
Neurological score=(blood pressure – mean blood 
pressure for age) + (mean heart rate for age – heart 
rate) + 25 × (AVPU coma scale)
In FEAST, scores were calculated at baseline (before 
commencing fluid administration) and 1 h, 4 h, 8 h, 24 h, 
and 48 h after commencing fluid bolus or maintenance 
fluids. In the other cohorts, only baseline data (ie, at 
enrolment) were used.
In FEAST, haemoglobin concentration and plasma 
lactate were measured at baseline, 8 h, and 24 h; base 
excess, pH, and electrolytes were measured at baseline 
and 24 h.3
Statistical analysis
All available data in each dataset were used 
(appendix pp 21, 22), with the exception of implausible 
blood biochemistry values in FEAST, which were 
excluded (base excess less than –30 mEq/L [n=2]; chloride 
<80 mmol/L [n=1]; bicarbonate=0 mmol/L [n=1]).
We calculated the odds of adverse outcome for each ten­
unit increase in baseline score using logistic regression. 
In FEAST and the UK meningococcal disease cohorts the 
outcome was death; in the Malawi cohort the outcome was 
neurological sequelae or death; in the South African 
cohort the outcome was admission to intensive care, or 
death; in the St Mary’s Hospital cohort the outcome was 
admission to hospital or intensive care.
To show the association of each physiological score 
with disease severity, and to gain insight into the 
association of the scores with specific pathophysiological 
phenotypes such as cerebral malaria and septic shock, we 
compared the distribution of scores between cohorts 
using the Mann­Whitney test.
Saline and albumin bolus were equally associated with 
increase in mortality in FEAST.3 Therefore we compared 
physiological scores and blood parameters between the 
combined group of albumin and saline­randomised 
individuals with those randomised to no bolus in an 
intention­to­treat analysis. For the primary analysis we 
used linear regression, controlling for baseline values 
(before starting fluid), to detect mean differences in 
physiological scores and blood variables between the 
bolus and no bolus groups at sequential timepoints after 
the start of fluid bolus or maintenance fluid (no bolus 
group) administration.
To examine whether bolus was associated with an 
increased proportion of patients with extreme derange ment 
of physiological parameters we created separate bins across 
the distribution of each variable, and then calculated the 
relative risk for bolus recipients versus no bolus recipients 
being in each bin. We did this for both change from baseline 
value, and for absolute values of each parameter.
To assess the effect of volume of fluid administered, we 
did a secondary analysis based on the actual volume of 
fluid boluses received within the first 2 h. On the basis of 
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the bimodal distribution, we categorised low volume as 
less than 30 mL/kg and high volume as 30 mL/kg or more. 
Because the decision to administer more than 20 mL/kg 
(initial bolus) was not randomised but was based on 
clinical assessment of ongoing impaired perfusion, we 
anticipated some bias due to severity of illness at baseline. 
We therefore analysed both change from baseline of each 
physiological score, biochemical variable, and haemo­
globin, as well as the actual distribution observed in high­
volume and low­volume bolus groups.
To identify subgroups with differing physiological 
derangement who might differ in response to fluids, we 
used Bayesian Dirichlet process clustering as implemented 
in the R package PreMiuM,27 applied to baseline physio­
logical scores and haemoglobin concentration and lactate 
measurements in all participants recruited to FEAST 
(appendix pp 6, 7). The modelling assumes variables are 
distributed as multivariate normal distributions within 
each cluster. We applied Cox proportional hazards 
regression to each identified cluster to compare survival 
times between the bolus and no bolus groups. In FEAST 
stratum A, we used Kaplan­Meier plots to visualise survival 
over time. We used Spearman correlation to assess the 
relationship between haemoglobin and lactate. 
To explore how the multiple simultaneous physiological 
changes caused by fluid bolus were associated with excess 
deaths in bolus recipients (the primary finding in FEAST) 
we examined the relationship between death and the 
combination of physiological scores, base excess, 
bicarbonate, chloride, and haemoglobin concentration in 
principal component analysis and Cox proportional hazard 
regression models (appendix pp 6–8). We built Cox 
proportional hazard models for time of death using bolus 
or no bolus, physiological scores, and imputed estimates 
of haemoglobin concentration and biochemical values at 
1 h after bolus administration (appendix pp 7, 8). Full 
details of the imputation and basis for minimal and larger 
estimates of each value are shown in the appendix (pp 7, 8, 
19, 28–31). The initial model included only bolus alone and 
additional covariates were added iteratively to the models 
in order of their association with outcome using a forward 
selection approach. After each iteration, we report the 
resulting hazard ratio for time of death. We repeated the 
procedure using the individual components of each 
physiological score rather than the composite scores, to 
identify the contribution of each variable to the increased 
mortality in bolus recipients. For comparison, we also built 
a multivariable model using measured baseline values of 
physiological scores and blood para meters. All statistical 
analyses were done in R (version 3.2.2). 
The FEAST trial is registered with ISRCTN, number 
ISRCTN69856593.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Details of each cohort are shown in table 1. In the 
FEAST study, median physiological scores were 105 
(IQR 86–124) for cardiovascular function, 53 (37–79) for 
respiratory function, and 25 (8–47) for neurological 
function. Patients in FEAST had significantly higher 
values of all physio logical scores than the St Mary’s 
Hospital cohort (57 [IQR 50–67] for cardiovascular 
function, 5 (0–12) for respiratory function, and 11 (3–20) 
for neurological function), and they had higher respiratory 
Setting Total (n) Entry criteria Age (months) Sex Outcome
n Median (IQR) n Male, n (%) n Adverse 
outcome
Adverse 
outcome, 
n (%)
FEAST Kenya, Uganda, 
and Tanzania
3170 Fever and respiratory distress or 
prostration and impaired 
perfusion
3170 24 (13–38) 3170 1705 (54) 3170 Death 315 (10)
Meningococcal 
disease
England, Wales, 
and Northern 
Ireland, UK 
502 Neisseria meningitidis culture or 
PCR positive or purpura fulminans 
without other cause
499 39 (13–166) 365 192 (53) 502 Death 148 (29)
Cerebral malaria Blantyre, Malawi 448 Blantyre coma score ≤2 with 
Plasmodium falciparum 
parasitaemia and no other 
discernible cause of coma
448 45 (29–67) 448 233 (52) 448 Death or 
neurological 
sequelae
106 (24)
South Africa Cape Town, 
South Africa
61 Suspected septic shock or severe 
gastroenteritis and clinician’s 
decision to give fluid resuscitation
61 5 (1–9) 61 36 (59) 61 Death or 
intensive care 
admission
20 (33)
St Mary’s Hospital 
emergency 
department
London, UK 18 863 Emergency department 
presentation
18 862 48 (18–110) 18 861 10 467 (55) 18 717 Admission to 
hospital ward or 
intensive care 
unit
1933 (10)
Table 1: Clinical details of cohorts studied
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scores than all other cohorts (p<0·0001; appendix p 9). 
Neurological scores were highest in the Malawian cerebral 
malaria cohort (median score 75, IQR 55–78; appendix 
p 9). FEAST patients had cardio vascular scores similar to 
those in the Gram­negative sepsis meningococcal cohort 
(median score 100, IQR 69–157; appendix p 9).
Physiological scores in FEAST were highest in the first 
hours following admission, and decreased over the next 
48 h (appendix p 9). Median physiological scores, at 
baseline and 48 h, respectively, were 105 (IQR 86–124) and 
52 (39–65) for cardiovascular score, 53 (37–79) and 18 
(11–27) for respiratory score, and 25 (8–47) and 4 (0–13) for 
neurological score. Patients who subsequently died had 
significantly higher respiratory and neurological scores 
than survivors at all timepoints up to 24 h (appendix p 9). 
Cardiovascular score was significantly higher in fatal 
cases than in survivors at baseline, was not significantly 
different at 1 h after administration of initial fluid bolus 
(if received), but was then significantly higher after 4 h or 
more in those dying than in survivors (appendix p 9).
In FEAST, odds of death for each ten­unit increase in 
baseline score was 1·09 (95% CI 1·07–1·11) for respiratory 
score, 1·26 (1·21–1·31) for neurological score, and 1·09 
(95% CI 1·05­1·14) for cardiovascular score (all p<0·0001; 
appendix p 22). The associations between physiological 
scores and outcome measures in the other cohorts are 
shown in the appendix (p 22).
To determine the effect of fluid bolus on physiological 
scores, biochemical parameters, and haemoglobin con­
centration, we used linear regression analysis to calculate 
the mean differences, adjusted for baseline value, between 
those randomly assigned to receive bolus or no bolus in 
FEAST. We combined the albumin and saline groups 
because they had similar effects on mortality in FEAST.3 
Mean respiratory score was 3·45 (95% CI 0·90–6·01; 
p=0·0080) higher at 1 h and 2·3 (0·31–4·3; p=0·024) 
higher at 4 h in children randomly assigned to receive 
bolus than in those who received no bolus, but there was 
no significant difference between groups at 12 h (table 2). 
Fluid bolus increased the mean neurological score at 1 h 
by 2·64 (95% CI 0·76–4·52, p=0·0060) and there was no 
significant difference at 4 h and 12 h (table 2). Conversely, 
fluid bolus decreased the mean cardiovascular score at 1 h 
by 2·17 (95% CI 0·57–3·78, p=0·0080; table 2); there was 
no significant difference between groups at 4 h and 12 h. 
After 4 h, there were no significant differences in 
physiological scores (table 2). In a post­hoc analysis, 
we analysed albumin and saline groups separately 
(appendix p 23). With the exception of respiratory score at 
8 h, which was more increased in albumin recipients than 
in saline recipients, there were no significant differences 
between participants who received saline and those who 
received albumin (appendix p 23). Bolus decreased mean 
haemoglobin concentration at 8 h by 0·33 g/dL (95% CI 
0·20–0·46, p<0·0001). Bolus was not associated with a 
change in blood lactate concentrations at 8 h or 24 h 
but was associated with a decrease in mean plasma 
bicarbonate by 0·96 mmol/L (0·45 to 1·47, p=0·0003), a 
decrease in mean base excess by 1·41 mEq/L (0·76 to 2·06, 
p<0·0001), and an increase in mean chloride by 1·65 
mmol/L (95% CI 0·47 to 2·83, p=0·0070) in patients 
surviving to 24 h (table 2).
To assess whether bolus induced larger changes in 
some individuals, we compared the proportions of 
individuals in different segments of the distribution of 
each variable between the bolus and no bolus groups 
(figure 2; appendix p 10). Compared with those who did 
not receive bolus, individuals who received bolus had an 
increased risk of a large or very large increase in 
respiratory score and neurological score at 1 h, and of a 
large or very large decrease in cardiovascular score at 1 h 
(figure 2). The bolus­associated changes in respiratory 
score persisted at 4 h (appendix p 10). When absolute 
values of scores at 1 h and 4 h were considered, rather 
than change from baseline, a greater proportion of the 
bolus group had high respiratory and neurological scores 
than in the no bolus group, whereas a smaller proportion 
had high cardiovascular score (appendix pp 11, 12). Larger 
n/N (%) Effect size* (95% CI); p value
Respiratory score
1 h 2925/3102 (94·3%) 3·45 (0·90 to 6·01); p=0·0080
4 h 2884/3025 (95·3%) 2·31 (0·31 to 4·31); p=0·024
12 h 2838/2938 (96·6%) 1·58 (–0·29 to 3·46); p=0·10
Neurology score
1 h 2992/3102 (96·5%) 2·64 (0·76 to 4·52); p=0·0060
4 h 2933/3025 (97·0%) 1·05 (–0·68 to 2·79); p=0·23
12 h 2881/2938 (98·1%) 0·322 (–1·30 to 1·94); p=0·70
Cardiovascular score
1 h 3010/3102 (97·0%) –2·17 (–3·78 to –0·57); p=0·0080
4 h 2948/3025 (97·5%) –0·30 (–1·93 to 1·33); p=0·72
12 h 2897/2938 (98·6%) 0·10 (–1·52 to 1·72); p=0·90
Haemoglobin (g/dL)
8 h 2771/2974 (93·2%) –0·33 (–0·46 to –0·20); p<0·0001
24 h 2723/2882 (94·5%) –0·21 (–0·35 to –0·08); p=0·0010
Lactate (mmol/L)
8 h 2737/2974 (92·0%) –0·12 (–0·33 to 0·092); p=0·27
24 h 2657/2882 (92·2%) –0·011 (–0·21 to 0·19); p=0·92
Base excess (mEq/L)
24 h 857/2882 (29·7%) –1·41 (–2·06 to –0·76); p<0·0001
Bicarbonate (mmol/L)
24 h 858/2882 (29·8%) –0·96 (–1·47 to –0·45); p=0·0003
Chloride (mmol/L)
24 h 840/2882 (29·1%) 1·65 (0·47 to 2·83); p=0·0070
Results of linear regression analysis comparing albumin or saline bolus with no 
bolus controls, controlling for respective baseline levels. Times shown are the 
hours after start of infusion. Proportions are given as a percentage of individuals 
with data from those alive at that timepoint. *Mean change in the variable 
relative to the no bolus control. A positive effect size indicates an increase in the 
parameter in bolus recipients; a negative effect size indicates a decrease in the 
parameter in bolus recipients, relative to the no bolus group. 
Table 2: Changes in physiological scores and blood parameters 
associated with fluid bolus in FEAST
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decreases from baseline in base excess and bicarbonate, 
and larger increases in chloride were observed in bolus 
recipients (figure 2D–F). A greater proportion of bolus 
recipients had very low haemoglobin concentration 
(<7·5 g/dL and <5 g/dL) at 8 h (appendix p 11).
In an exploratory analysis, we assessed the effect of low 
or high volume bolus on the distribution of physiological 
scores and blood parameters. At 4 h, the first observation 
after completion of the high volume bolus, there were 
higher respiratory and neurological scores in patients 
who received high volume (≥30 mL/kg) bolus 
(appendix p 13). However, the distribution of cardio­
vascular scores at 4 h was similar in low and high volume 
recipients (appendix p 13). There were lower base excess 
and bicarbonate, higher chloride, and lower haemoglobin 
concentration (but only in untransfused participants) in 
the high­volume bolus recipients (appendix p 13). 
Findings were similar when change from baseline was 
considered (appendix p 14).
The biochemical changes we observed in FEAST 
suggested that boluses of albumin or saline could cause 
hyperchloraemic metabolic acidosis. To explore this 
further, we did a post­hoc analysis of the effect of bolus 
on pH and respiratory compensation. 719 (35%) of 
2082 FEAST participants with pH measurements at 
baseline had acidosis (pH<7·35; appendix p 15), and the 
mortality rate for those with baseline acidosis was much 
higher than for those with pH of 7·35 or higher. Among 
survivors in the bolus group, the relative risk of being 
acidotic at 24 h was 1·4 (95% CI 1·0–1·9) compared with 
the no bolus group. There was a significant negative 
correlation between chloride and pH, with a stronger 
effect of chloride on pH in the bolus group (appendix 
p 15). Low pH suggests that respiratory compensation 
mech anisms have been overwhelmed, so we explored the 
respiratory response at early timepoints, when the 
majority of deaths occurred in acidotic patients. 
Respiratory rates were increased at baseline and 1 h, 
relative to normal ranges for healthy children  (appendix 
p15). Oxygen saturations decreased more in bolus 
recipients at 1 h, whereas there were no differences 
between the bolus and no bolus groups in the change in 
respiratory rate (appendix p 15).
We identified three clusters of patients on the basis of 
their baseline characteristics (figure 3A). Cluster 
one (n=1991) had least derangement in physiological 
scores, haemoglobin concentration, and lactate. Cluster 
two (n=795) comprised patients with severe anaemia 
(haemoglobin concentration <5 g/dL), and high lactate and 
cardiovascular score. Cluster two also had greater base 
deficit, lower bicarbonate, and high chloride concentrations 
(appendix p 17). Cluster three (n=384) was characterised by 
Figure 2: Changes in physiological scores and blood measures associated with fluid bolus
The proportion of individuals in FEAST with different magnitudes of change from baseline in physiological scores and blood measurements are shown according to whether they were randomly assigned 
to receive no fluid bolus (red bars) or fluid bolus (blue bars). Panels A–C show changes in physiological scores between baseline and 1 h after starting fluid infusion. Panels D–F show changes in biochemical 
measures from baseline to 24 h. Panels G and H show change in haemoglobin concentration from baseline to 8 h in non-transfused (G) and transfused (H) participants. Negative values indicate decrease 
from the baseline, and positive values indicate increase from baseline. Values above the bars show relative risk (95% CI) for comparison of proportions between bolus and no bolus groups.
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extremely high respiratory and neurological scores, but 
better maintained haemoglobin concentration.
The clusters differed markedly in mortality (figure 3B). 
In cluster one, six (1%) of 658 participants in the non­
bolus group died, and 51 (4%) of 1327 died in the bolus 
group. In cluster two, 37 (14%) of 264 patients in the non­
bolus group died, and 108 (21%) of 518 died in the bolus 
group. Mortality was highest in cluster three: 32 (26%) of 
122 participants in the non­bolus group died, and 
59 (23%) of 252 in the bolus group died.
Considering all participants, there was a negative 
correlation between haemoglobin and lactate concen­
trations (Spearman r=–0·56, p<0·0001; figure 3C). 
Associations between bolus and respiratory score, neuro­
logical score, haemoglobin concentration, and blood 
biochemistry in clusters one and two were consistent with 
those seen in FEAST overall (appendix pp 24–26). The 
association between bolus and changes in  blood 
parameters and physiological scores in each cluster are 
shown in the appendix (pp 25–27).
We reasoned that the multiple physiological changes 
induced by bolus might act in combination to explain 
the higher mortality observed in the bolus group, 
and investigated this in post­hoc analyses. Principal 
component analysis using the physiological scores and 
predicted values of blood parameters at 1 h showed that the 
distribution of fatal cases was distinct from survivors and 
appeared related to the effects of bolus (appendix p 18). 
Baseline values of these variables predicted deaths in both 
bolus and no bolus groups, but there were more observed 
deaths in the bolus group, indicating that the baseline 
values of the covariates did not explain the difference in 
mortality (as expected in a randomised trial; appendix p 32). 
However, when we used the 1 h post­bolus values to predict 
deaths, using either conservative or more realistic 
estimates of the biochemical changes induced by bolus at 
1 hour (appendix pp 7, 8, 28–32), we found that there was 
no longer a significant difference between the bolus and 
no bolus groups (figure 4; appendix p 32). This finding 
indicates that the covariates in the model can explain all of 
the difference in observed mortality between bolus and no 
bolus groups of the trial. We found that after bolus, the 
neurological score, base excess, and respiratory score were 
the major determinants of the increased death rate from 
Figure 3: Bayesian cluster analysis of FEAST
(A) Distributions of the physiological scores, haemoglobin concentrations, and lactate concentrations by cluster. Boxes show median (coloured line) and IQR; 
whiskers extend up to 1·5 times IQR. Cluster one, n=1991; cluster two, n=795; cluster three, n=384. (B) Survival curves for no bolus (red line) or bolus (blue line) 
recipients in each cluster in FEAST stratum A. Cluster one, bolus n=1327, no bolus n= 658; cluster two, bolus n=518, no bolus n=264; cluster three, bolus n=252, no 
bolus n=122. Dotted lines indicate 95% CIs. (C) Correlation between baseline haemoglobin and lactate concentrations (Spearman p<0·0001, rs–0·56) with individual 
participants coloured by cluster (cluster one [red] n=1991; cluster two [green] n=795; cluster three [blue] n=384).
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bolus using either minimal (figure 4A) or more realistic 
estimates (figure 4B) of the post­bolus biochemical values 
(appendix). When the individual components of each score 
were included in the models, the post­bolus AVPU score, 
base excess, and oxygen saturation made the largest 
contribution to explaining the excess deaths (figure 4C, 
4D). We summarised these findings into a physiological 
model proposing how the adverse effects of bolus fluids 
could increase mortality (figure 5).
Discussion
The physiological scores we developed provide a tool to 
quantify changes in respiratory, cardiovascular, and 
neurological function in response to bolus fluids in 
FEAST. The scores discriminated between cohorts of 
patients with infections affecting different organ systems 
and were generally predictive of outcome, showing their 
use as objective measures of organ system derangement. 
Using these physiological scores and available blood 
measurements, we observed six deleterious effects of fluid 
bolus: respiratory and neurological scores increased at 
early timepoints; haemoglobin concentration decreased 
(particularly in patients who did not receive blood 
transfusion); base deficit and chloride concentrations 
increased, and plasma bicarbonate decreased (changes 
consistent with hyperchloraemic acidosis). Although 
the linear regression analysis showed a modest, but 
significant, change in the mean value of each variable, 
there were much greater changes observed in some 
individuals, with increased proportions of bolus recipients 
having extreme adverse physiological derangement in 
physiological scores, haemoglobin concentration, and 
blood chemistry. Most of these changes were greater in 
patients receiving higher fluid volumes. The changes in 
physiological scores were most evident at early timepoints, 
but early deaths and the increased mortality in bolus 
recipients makes evaluation of later timepoints difficult. 
The only beneficial physiological change observed was a 
reduction of cardiovascular score, in keeping with the 
impression of clinicians that perfusion improved during 
fluid resuscitation.
When we included the bolus­induced changes in 
respiratory function, cardiovascular function, neuro logical 
function, and biochemical changes in Cox survival models, 
the increased mortality in bolus recipients in FEAST was 
explained by the physiological changes we identified. 
Analysis of the effect of each component in the models 
showed that the excess deaths in bolus recipients were 
largely explained by worsening neurological score (or 
raised intracranial pressure), increased base deficit, and 
worsening respiratory score. Of the individual components 
analysed, bolus­induced increased base deficit, worsening 
conscious level, and oxygen saturation were the major 
contributors to the excess mortality associated with bolus.
Since the 1990s, there have been increasing reports, 
including small case studies, randomised trials in healthy 
volunteers and patients, and experimental studies in 
animals that have documented hyperchloraemic acidosis 
after infusion of unbuffered salt solutions (appendix 
pp 28–31).30–33 Hyperchloraemic acidosis is an inevitable 
consequence of the infusion of unbuffered sodium 
chloride solutions, predicted by the Stewart equation of 
acid­base balance28,29 and confirmed in the extensive 
literature. Although many small studies comparing 
balanced salt solutions (which contain acetate or lactate 
as a source of anion) with normal saline have documented 
saline­induced hyperchloraemic acidosis, recent large 
clinical trials also reported increased mortality and 
worsening renal outcome in adults receiving normal 
saline as compared with balanced salt solutions.34,35 Our 
finding that the bolus­induced hyperchloraemic acidosis 
and decreased base excess was a major contributor to the 
increased mortality in bolus recipients suggests that 
much of the adverse effect of bolus in FEAST was due to 
the nature of the fluids used.
Worsening respiratory function and increase in signs of 
raised intracranial pressure, which we documented in 
Figure 4: Contribution of physiological derangements to excess mortality due to bolus
In post-hoc analyses, we calculated hazard ratios for bolus versus no bolus on time of death in Cox proportional 
hazard models, sequentially incorporating additional explanatory covariates (in order from top to bottom of each 
list), showing how the effect of bolus on death is mediated by observed changes in physiology and blood 
parameters (A–D). Up or down refers to the direction of change from the age-related mean values, which 
contribute to different physiological scores. (A) The covariate list includes physiological scores at 1 h and 
conservative (data-derived) estimates of the effect of bolus on blood parameters at 1 h. (B) The covariate list uses 
literature-derived values for the changes in acid-base biochemistry parameters. (C) The covariate list includes the 
component variables of the physiological scores at 1 h and conservative (data-derived) estimates of the effect of 
bolus on blood parameters at 1 h. (D) The covariate list uses literature-derived values for the changes in acid-base 
biochemistry parameters. Analyses in A–D are based on 1898 subjects with complete data for physiological scores 
at 1 h and baseline biochemical parameters. AVPU= Alert, Responds to Voice, Responds to Pain, Unresponsive.
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bolus recipients, are well known effects of fluid 
administration in some critically ill patients. Indeed, 
many guidelines for management of shock recommend 
intubation, and elective mechanical positive pressure 
ventilation for patients who remain with signs of shock 
after initial bolus volume infusion because of the 
recognition that continued fluid resuscitation is likely to 
cause respiratory deterioration.1,36 However, our finding 
that small volumes (20–40 mL/kg) of normal saline or 
albumin, which are routinely administered to under­
perfused children in emergency departments, cause 
worsening of respiratory function and decrease in oxygen 
saturation suggest that even modest volumes of fluid 
might have detrimental effects in some children despite 
the observable improvement in perfusion, which was also 
manifested in FEAST as improving cardiovascular score. 
Our findings raise the possibility that administration of 
fluid bolus to underperfused patients might increase the 
need for intensive care admission because of worsening 
oxygenation.
The worsening neurological score in bolus recipients 
and the contribution of deteriorating neurological score 
to the excess mortality in bolus recipients is also an 
expected effect of bolus fluids in patients who have 
increased intracranial pressure. More than 50% of the 
patients included in FEAST had severe malaria, and 
many of these patients had evidence of cerebral malaria. 
Evidence of raised intracranial pressure has been well 
documented in cerebral malaria by direct measurement,37 
MRI scan,20 and by clinical findings.38 Both fluid volume 
and the hyperchloraemic acidosis induced by the saline 
and albumin used in FEAST could have contributed to 
the worsening of consciousness and neurological score in 
bolus recipients (figure 5). Although patients with 
neurological diseases such as cerebral malaria and 
meningitis comprise a smaller proportion of critical 
illness in resource­rich settings, our finding that 
worsening neurological score occurred in bolus recipients 
suggests that volume resuscitation should be used with 
great caution in patients presenting with neurological 
illness, and unbuffered salt solutions should be avoided.
Our cluster analysis revealed heterogeneity within 
FEAST. The majority of patients (cluster one), had least 
severe derangement of all three physiological scores, 
adequate haemoglobin concentrations, and remarkably 
low mortality in the absence of bolus. Fluid bolus in this 
cluster caused worsening of respiratory and neurological 
function, reduced haemoglobin concentration and 
increased acidosis. The second cluster, characterised by 
low haemoglobin concentration, high lactate concen­
tration, and high cardiovascular score, identified patients 
with severe anaemia. The inverse relationship observed 
between haemoglobin and lactate concentrations, and 
lower bicarbonate and base excess suggests that the 
baseline hyperlactataemia and metabolic acidosis is largely 
driven by impaired oxygen carrying capacity. In this cluster, 
Figure 5: Proposed physiological model of the adverse effects of fluid bolus 
Bolus fluid reduces haemoglobin concentration, resulting in decreased tissue oxygenation, increasing anaerobic metabolism, and metabolic acidosis. According to 
the Stewart model, maintenance of normal plasma pH is controlled by (1) the strong ion difference (charge difference between strong cations (Na+, K+, Ca2+, and 
Mg2+), and strong anions (Cl– and lactate–); (2) pCO2 and (3) charge from weak acids (phosphate, albumin).28,29 Bolus of normal saline or 5% albumin (which have 
similar electrolyte content) caused hyperchloraemia and dilution of bicarbonate, resulting in a reduction in the strong ion difference. Hyperchloraemic acidosis 
increases the need for respiratory compensation through increased carbon dioxide excretion to maintain pH. Worsening of respiratory function due to bolus results in 
hypoxia (as evidenced by low oxygen saturation and increased respiratory score). This outcome, together with an inability to increase respiratory rate, impairs 
excretion of carbon dioxide (not shown in our study). Increasing carbon dioxide causes cerebral vasodilation, resulting in increased intracranial pressure. Fluid bolus 
might also directly cause cerebral oedema. The combination of adverse effects on haemoglobin concentration, acidosis, and respiratory and neurological function 
induced by modest albumin or saline fluid boluses might overwhelm compensatory mechanisms in the most severely ill patients, resulting in increased mortality. 
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bolus fluids caused worsening of respiratory and neuro­
logical function and increased acidosis. The third cluster, 
characterised by high respiratory and neurological scores 
had high mortality (23–26%). Patients in the bolus 
group had lower haemoglobin concentrations and higher 
chloride concentrations than those in the non­bolus group.
Identification of clusters within the large FEAST cohort 
of ill children has important therapeutic implications. 
The low mortality in the absence of bolus fluids in cluster 
one suggests that this group did not require any 
additional intervention, and most would recover with 
treatment of the infection alone. In cluster two, in which 
anaemia was the major problem, we believe blood 
transfusion was required, and bolus probably worsened 
tissue oxygen delivery. In cluster three, in which 
respiratory failure and neurological impairment were the 
main physiological derangements, we believe that 
respiratory support was needed to reduce mortality.
Combination of the physiological derangements 
caused by bolus explained mortality better than the pre­
bolus values of the same parameters, indicating that 
through their combined effects, the bolus­induced 
changes plausibly explain the effect of bolus on mortality 
in FEAST (figure 4). Because the physiological changes 
identified are likely to be similar in all settings, our 
findings have implications for fluid resuscitation in both 
developed and resource­limited settings, although the 
magnitude of effect may differ because the severity of 
anaemia in FEAST participants might have increased the 
relative importance of haemodilution.
The findings in our analysis differ from the previous 
analysis of modes of death in FEAST9,22 and an ovine 
model,39 which concluded that worsening cardiovascular 
shock was the major adverse effect of bolus. The earlier 
study22 used increased plasma lactate concentration as 
part of the definition of cardiovascular shock. Our 
analysis found that plasma lactate was negatively 
correlated with haemoglobin concentration, and thus use 
of lactate as a biomarker of cardiovascular shock in the 
previous analysis gave an incorrect indication of the 
prevalence of cardiovascular shock.
Our study has several limitations. Although our physio­
logical scores are associated with outcome in multiple 
different cohorts, they have not been independently 
validated. In particular, the weightings were chosen to 
reflect the perceived importance of each variable as a 
measure of organ system function. They were not derived 
from the data or from previous studies. The scores should 
be seen as means of studying changes in physiology 
between arms of a trial, rather than as outcome predictors, 
for which there are already a number of scoring systems 
available.15–18 FEAST was done in settings in which 
intensive care and mechanical ventilation were not 
available. Although the physiological changes induced by 
bolus are likely to be seen in all settings, caution is needed 
in extrapolating associations with mortality to resource­
rich settings, in which some of the adverse effects of bolus 
fluids could be mitigated by mechanical ventilation and 
neuro­intensive care. Furthermore, because of the design 
of the trial, we cannot exclude that the associations we have 
reported between greater physiological derangements and 
larger volumes of administered fluid are confounded by 
the indication—ie, administration of larger volumes of 
fluid to participants with more deranged physiology. An 
additional limitation is that acid­base balance was only 
measured on admission and at 24 h, by which time most 
deaths had occurred, and many patients had no data at the 
24 h timepoint. To include the effect of bolus on acid­base 
balance, we imputed the earlier timepoints from the 24 h 
differences, and used published values to produce a range 
of estimates of the extent of acidosis at earlier time points. 
We believe the assumptions used in the imputation 
provide reliable estimates of the earlier values.
The FEAST trial included children with widely differing 
diseases and underlying physiology. We found that fluid 
bolus achieved the intended improvement in cardiovascular 
function at the cost of worsening respiratory and neuro­
logical function, acidosis, and reduced haemoglobin. Our 
finding that within FEAST there are clusters with differing 
physiological derangements suggests particular need for 
caution in fluid administration to patients with established 
respiratory failure, neurological failure, severe acidosis, or 
anaemia, and the need for better detection and specific 
management of the physiological derangements in each 
individual patient. The physiological scores we have 
developed might be useful in identifying derangement in 
specific organ systems.
The combination of adverse physiological effects we 
observed, associated with both albumin and saline bolus, 
raises questions about both the volume and type of fluid 
used in resuscitation. Balanced salt solutions such as 
Ringer’s lactate or plasmalyte (which have electrolyte 
compositions closer to plasma than normal saline, and 
lactate or acetate as major anions) are associated with 
more rapid resolution of acidosis than 0·9% saline, and 
in recent clinical trials they were associated with 
improved outcomes.34,35,40 Our finding that worsening 
hyperchloraemic acidosis was a major contributor to the 
excess deaths in FEAST suggests that unbalanced salt 
solutions such as normal saline and 5% albumin should 
be avoided in seriously ill patients and replaced with 
balanced salt solutions. However, other fluids are likely 
to have the same adverse effects on respiratory function, 
oxygen carrying capacity, and perhaps neurological 
function that we have observed with albumin and saline 
in FEAST. Trials are needed to establish if balanced 
electrolyte solutions and lower volumes than currently 
recommended will allow the benefits of fluid on 
cardiovascular function to be achieved without the 
adverse effects observed in FEAST.
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